Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arcion Therapeutics Inc.

www.arciontherapeutics.com

Latest From Arcion Therapeutics Inc.

Deals In Depth: March 2013

AstraZeneca paid $240 million for rights to Moderna’s RNA therapeutics. Argon Medical acquired Angiotech’s interventional business for $362.5 million. PIPEs accounted for 31% of the $976 million in biopharma financing. FOPOs, on the other hand, dominated the $523 million in device fundraising.

BioPharmaceutical Medical Device

IN VIVO: Deals Shaping The Medical Industry, May 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

Pain Drug Development Becomes Personalized

Advances in pain neurobiology point to the promise of more specific drugs with fewer side effects, yet the field continues to show few successes. Nevertheless, fast-advancing knowledge, a huge market, and better clinical study de-risking strategies should eventually overcome investor shyness about backing emerging personalized pain drug developers.

BioPharmaceutical United States

Personalized Pain Drug Development

Fast-advancing knowledge, a huge market, and better clinical study de-risking strategies should eventually overcome investor shyness about backing emerging personalized pain drug developers. We profile three new entrants in this issue: Adynxx, Afferent Pharmaceuticals, and Katama Pharmaceuticals.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Arcion Therapeutics Inc.
  • Senior Management
  • James N Campbell, MD, Pres. & CEO
    William K Schmidt, PhD, VP, Clin. & Reg.
  • Contact Info
  • Arcion Therapeutics Inc.
    Phone: (410) 522-8701
    2400 Boston St.
    Ste. 330
    Baltimore, MD 21224
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register